On November 7, 2019 OSE Immunotherapeutics (ISIN: FR0012127173; Mnémo: OSE), reported a new licensing deal with Chong Kun Dang (CKD) Pharmaceutical Corporation for Tedopi, a combination of neoepitopes selected and optimized from five tumor antigens shown to generate a specific response of cytotoxic T cells versus cancer cells expressing at least one of these tumor associated antigens and an associated T-helper cell response, for potential registration and commercialization in Korea (Press release, OSE Immunotherapeutics, NOV 7, 2019, View Source [SID1234648650]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are pleased to announce the licensing of Tedopi to such a strong partner as CKD, one of the industry leaders in Korea," said Alexis Peyroles, Chief Executive Officer of OSE Immunotherapeutics. "This partnership allows us to make a difference for Korean non-small cell lung cancer patients after previous checkpoint inhibitor treatment failure, a population for which there is great unmet medical need. This licensing agreement is an example of our commitment to making Tedopi available to the broadest audience globally and maximizing its potential."
Financial terms of the contract include both upfront and short-term milestone payments of €1.2 million with total milestones payments of €4.3 million, as well as royalties on sales and transfer price in the high twenties. The deal applies specifically to development and licensing of Tedopi in the Korean market which accounts for approximately 1% of the total global oncology market.
"It is indeed interesting times as cancer immunotherapies are dramatically transforming the landscape of cancer treatment. However, there is a large population still devastated from checkpoint inhibitor failures," said Young-Joo Kim, Chief Executive Officer of Chong Kun Dang Pharmaceutical Corp. "We are excited to add a promising product to help an underserved patient population to our portfolio and look forward to working with the outstanding team at OSE to help bring Tedopi to the Korean market."
Tedopi is currently being evaluated in an open-label Phase 3 trial (called Atalante 1) in advanced non-small cell lung cancer (NSCLC) for HLA-A2 positive patients after failure from previous treatment with PD-1/PD-L1 checkpoint inhibitors. Results from the first step of this ongoing Tedopi Phase 3 trial in NSCLC are expected end of Q1 2020.Tedopi is also being studied in an ongoing Phase 2 trial in patients with pancreatic cancer.